What are the specific functional and therapeutic scopes of Avonib/Tosovo?

Ivosidenib (Ivosidenib) is a targeted drug with "inhibiting mutant IDH1 enzyme activity" as its core mechanism. Its unique feature is that it affects disease progression by regulating abnormal metabolism of tumor cells, which makes it have potential value in multiple hematological and solid tumor fields. Currently, the main internationally recognized indications include specific mutation types related to acute myeloid leukemia (AML), cholangiocarcinoma (CCA), and some myelodysplastic syndromes (MDS).

In the AML field, ivonib is not positioned as a substitute for traditional chemotherapy, but as a replacement drug based on precision treatment. The core target of AML is the arrest of cell differentiation caused by IDH1 mutations. Therefore, the drug helps abnormal cells restore the direction of differentiation by reversing the accumulation of metabolites. Therefore, it is used in patients who are not suitable for intensive chemotherapy, and is also used in relapsed or refractory situations. The benefit brought by its targeting mechanism is that the side effect spectrum is more controllable than traditional chemotherapy, allowing some patients to maintain a better living condition during treatment.

Cholecystocarcinoma (CCA) is another approved area. IDH1 mutations occur more frequently in some people with cholangiocarcinoma, and traditional treatment options are limited. Therefore, ivonib provides a new treatment option for this type of patients. Its mechanism is also based on metabolic regulation, helping to inhibit the continued growth of tumor cells. Overseas guidelines have included it in the treatment pathway for cholangiocarcinoma with clear mutation indications.

In terms ofMDS, although the registration status varies in different regions, international literature and research have paid attention to the pathological characteristics of IDH1 mutation subtypes in MDS, and therefore ivonib has been used as a potential solution for metabolic pathway targeted therapy in specific patient groups.

Overall, the common feature of the indications for ivonib is "based on mutation screening" and not universal use, which also means that IDH1 testing needs to be performed before treatment to determine whether it is suitable.

Reference: https://www.tibsovo.com/